NutriFlex Lipid Plus Injection

Adult administration

Administered via central venous access. The rate of administration should be determined considering the total administered amount, the characteristics of the final mixed solution, the daily dosage, and administration time. Typically, the amount to be administered is gradually increased over the first 30 minutes until an appropriate dosage is reached. The maximum infusion rate should not exceed 2.0 mL/kg/hour. (Amino acids 0.08 g/kg per hour, dextrose 0.24 g/kg, lipids 0.08 g/kg)

This medication should be used strictly according to a doctor's instructions, and administration must be immediately discontinued if any allergic reactions such as fever, tremors, rash, or difficulty breathing occur. When used with intravenous calcium preparations, avoid mixing or administering simultaneously. If the same infusion line is to be used, thorough washing is required. Particularly in premature or low birth weight infants, lipid metabolism can be challenging and pose risks, so caution is necessary. Do not administer to specific patient populations such as premature infants, neonates, those with allergies to eggs or soybean oil, and patients with severe renal or liver disease. In patients with renal failure, liver dysfunction, heart failure, diabetes, and other specific conditions, administration should be cautious, and blood lipid and electrolyte levels should be monitored frequently. Overdosage or rapid infusion can cause side effects; if symptoms such as fever, shaking, vomiting, or difficulty breathing appear, discontinue administration immediately. Long-term use may result in liver dysfunction or blood abnormalities, so regular testing is required. Before administration, fluid, electrolyte, and acid-base balance should be improved, and blood glucose and lipid levels should be monitored periodically. This medication may interact with other drugs; thus, consult with a specialist if other medications are being taken. During pregnancy or breastfeeding, the safety of this medication has not been established, so it should be administered with caution. When conducting blood tests, the lipid components in this medication may affect the test results, so it is advisable to have blood drawn 5 to 6 hours after administration. Severe symptoms such as acidosis, fluid overload, hyperglycemia, and dehydration may occur with overdose, so adhere strictly to dosage and administration rate. Do not use if the packaging is damaged or if the solution has deteriorated. Administer immediately after opening, and do not reuse any remaining solution. Ensure to maintain aseptic conditions during preparation for administration, and store in a sealed container protected from light at a cool temperature of 15 to 25°C; avoid freezing.

Serious side effects

Anaphylactic reactions (rash, difficulty breathing, fever, shaking), hepatomegaly and jaundice, lipid overloading syndrome (including coma), hyperlipidemia, severe allergic reactions, difficulty breathing, severe swelling, bleeding, coagulopathy, thrombocytopenia, leukopenia, alterations or decreases in coagulopathy components, hyperlipidemia, liver dysfunction, acute pulmonary edema, overload syndrome, nonhypertrophic cardiomyopathy, acute myocardial infarction or cerebrovascular accident, severe sepsis.

Mild side effects

Fever, sweating, shaking, headache, vomiting, loss of appetite, nausea, pain in the back, bones, and chest, increased or decreased blood pressure, skin reddening, cyanosis, abdominal pain, fatigue, fever, flushing, chills, tremors, venous irritation symptoms such as phlebitis, thrombotic phlebitis.

This medication should be stored in a sealed container to avoid exposure to air and light, preferably in a cool temperature range of 15 to 25 degrees Celsius.

Appearance

An emulsion for infusion, colorless and transparent, contained in a bag made of polyamide and polypropylene divided into three compartments: two on the top and one on the bottom.

Package unit

bag - 1875 milliliters/bag